A new approach to ELISA-based anti-glycolipid antibody evaluation of highly adhesive serum samples.

[1]  Toshio Shimizu,et al.  A morphometric study of the vagus nerve in amyotropic lateral sclerosis with circulatory collapse , 2011, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[2]  S. Kusunoki,et al.  [Autoimmune neuropathies: diagnosis, treatment, and recent topics]. , 2011, Brain and nerve = Shinkei kenkyu no shinpo.

[3]  H. Willison.  Biomarkers in experimental models of antibody‐mediated neuropathies , 2011, Journal of the peripheral nervous system : JPNS.

[4]  A. Pestronk,et al.  Motor neuropathies and serum IgM binding to NS6S heparin disaccharide or GM1 ganglioside , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[5]  R. Yu,et al.  Membrane glycolipids in stem cells , 2010, FEBS letters.

[6]  M. Dalakas.  Pathogenesis and Treatment of Anti-MAG Neuropathy , 2010, Current treatment options in neurology.

[7]  N. Latov,et al.  Demyelinating Findings in Typical and Atypical Chronic Inflammatory Demyelinating Polyneuropathy: Sensitivity and Specificity , 2009, Journal of clinical neuromuscular disease.

[8]  N. Yuki,et al.  Electrophysiologic and immunopathologic correlates in Guillain–Barré syndrome subtypes , 2009, Expert review of neurotherapeutics.

[9]  Megumi Suzuki,et al.  Amyotrophic lateral sclerosis associated with IgG anti-GalNAc-GD1a antibodies , 2008, Clinical Neurology and Neurosurgery.

[10]  E. Nobile‐Orazio,et al.  How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? , 2008, Journal of the Neurological Sciences.

[11]  D. Annane,et al.  Immunotherapy for Guillain-Barré syndrome: a systematic review. , 2007, Brain : a journal of neurology.

[12]  R. Yu,et al.  Ganglioside Molecular Mimicry and Its Pathological Roles in Guillain-Barré Syndrome and Related Diseases , 2006, Infection and Immunity.

[13]  I. Utsunomiya,et al.  AIDP and CIDP having specific antibodies to the carbohydrate epitope (–NeuAcα2–8NeuAcα2–3Galβ1–4Glc–) of gangliosides , 2005, Journal of the Neurological Sciences.

[14]  T. Miyatake,et al.  Effect of Rabbit Anti-Asialo-GM1 (GA1) Polyclonal Antibodies on Neuromuscular Transmission and Acetylcholine-Induced Action Potentials: Neurophysiological and Immunohistochemical Studies , 2004, Neurochemical Research.

[15]  I. Niebroj-Dobosz,et al.  Serum IgM anti‐GM1 ganglioside antibodies in lower motor neuron syndromes , 2004, European journal of neurology.

[16]  H. Shibasaki,et al.  Amyotrophic lateral sclerosis with IgM antibody against gangliosides GM2 and GD2. , 2003, Internal medicine.

[17]  H. Willison,et al.  Peripheral neuropathies and anti-glycolipid antibodies. , 2002, Brain : a journal of neurology.

[18]  Moses Rodriguez,et al.  ICAM-1 is crucial for protection from TMEV-induced neuronal damage but not demyelination , 2002, Journal of NeuroVirology.

[19]  T. Miyatake,et al.  Recent studies on the roles of antiglycosphingolipids in the pathogenesis of neurological disorders , 2001, Journal of neuroscience research.

[20]  H. Hartung,et al.  Preceding infections, immune factors, and outcome in Guillain–Barré syndrome , 2001, Neurology.

[21]  Kai Simons,et al.  Lipid rafts and signal transduction , 2000, Nature Reviews Molecular Cell Biology.

[22]  S. Hakomori.  Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain , 2000, Glycoconjugate Journal.

[23]  I. Niebroj-Dobosz,et al.  Immunochemical quantification of glycoconjugates in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients , 1999, European journal of neurology.

[24]  K. Iwabuchi,et al.  Separation of “Glycosphingolipid Signaling Domain” from Caveolin-containing Membrane Fraction in Mouse Melanoma B16 Cells and Its Role in Cell Adhesion Coupled with Signaling* , 1998, The Journal of Biological Chemistry.

[25]  G. Stoll,et al.  Serum and CSF levels of soluble intercellular adhesion molecule‐1 (ICAM‐1) in inflammatory neurologic diseases , 1993, Neurology.

[26]  M. Blaser,et al.  Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China , 1993, Annals of neurology.

[27]  A. Hays,et al.  IgM deposits at nodes of ranvier in a patient with amyotrophic lateral sclerosis, anti‐GM1 antibodies, and multifocal motor conduction block , 1990, Annals of neurology.

[28]  S. Takahashi,et al.  Cell-adhesive immunoglobulin M in human plasma. , 1989, Biochemistry.

[29]  A. Pestronk,et al.  Patterns of serum IgM antibodies to GM1 and GD1a gangliosides in amyotrophic lateral sclerosis , 1989, Annals of neurology.

[30]  A. Pestronk,et al.  Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis , 1988, Neurology.

[31]  D. Michaelson,et al.  Antibodies to ganglioside GM1 in patients with Alzheimer's disease , 1988, Neuroscience Letters.

[32]  J. Wagner,et al.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. , 1968, Journal of theoretical biology.

[33]  I. Utsunomiya,et al.  AIDP and CIDP having specific antibodies to the carbohydrate epitope (-NeuAcalpha2-8NeuAcalpha2-3Galbeta1-4Glc-) of gangliosides. , 2005, Journal of Neurological Sciences.

[34]  R. Yu,et al.  Development regulation of ganglioside metabolism. , 1994, Progress in brain research.

[35]  R. Yu,et al.  Gangliosides: structure, isolation, and analysis. , 1982, Methods in enzymology.

[36]  L. Svennerholm.  THE GANGLIOSIDES. , 1964, Journal of lipid research.

[37]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .